Editorial comment on “Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study)”

Ähnliche Einträge

• Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety ( TATE study)
  von: H. James Wedner, et al.
  Veröffentlicht: (2024)
• Pediatric allergy and immunology in North America—An introduction
  von: Bianca Olivieri, et al.
  Veröffentlicht: (2025)
• Editorial comment: Socioeconomic deprivation performs equally to race in the Pediatric Asthma Risk Score
  von: Mark Kačar, et al.
  Veröffentlicht: (2026)
• Editorial comments on “Risk and protective factors of asthma and mental health condition multimorbidity in a national sample of Canadian children”
  von: Ozge Can Bostan, et al.
  Veröffentlicht: (2024)
• Editorial comment on “Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis”
  von: Umit Murat Sahiner, et al.
  Veröffentlicht: (2024)